Results 71 to 80 of about 7,344,221 (251)

Subpar reporting of pre‐analytical variables in RNA‐focused blood plasma studies

Molecular Oncology, Volume 19, Issue 7, Page 1968-1978, July 2025.
Pre‐analytical variables strongly influence the analysis of extracellular RNA (cell‐free RNA; exRNA) derived from blood plasma. Their reporting is essential to allow interpretation and replication of results. By evaluating 200 exRNA studies, we pinpoint a lack of reporting pre‐analytical variables associated with blood collection, plasma preparation ...
Céleste Van Der Schueren, Philippe Decruyenaere, Francisco Avila Cobos, Johanna Bult, Jill Deleu, Laudonia Lidia Dipalo, Hetty Hilde Helsmoortel, Eva Hulstaert, Annelien Morlion, Elena Ramos Varas, Kathleen Schoofs, Wim Trypsteen, Eveline Vanden Eynde, Hanne Van Droogenbroeck, Kimberly Verniers, Jo Vandesompele, Anneleen Decock   +16 more
wiley   +1 more source

Identification of functional and diverse circulating cancer‐associated fibroblasts in metastatic castration‐naïve prostate cancer patients

Molecular Oncology, Volume 19, Issue 7, Page 2074-2091, July 2025.
Cancer‐associated fibroblasts (CAFs) promote cancer growth, invasion (metastasis), and drug resistance. Here, we identified functional and diverse circulating CAFs (cCAFs) in patients with metastatic prostate cancer (mPCa). cCAFs were found in higher numbers and were functional and diverse in mPCa patients versus healthy individuals, suggesting their ...
Richell Booijink, Leon W. M. M. Terstappen, Eshwari Dathathri, Khrystany Isebia, Jaco Kraan, John Martens, Ruchi Bansal   +6 more
wiley   +1 more source

COAGULATION AND FIBRINOLYTIC ACTIVITY INDICES IN PATIENTS WITH IHD AFTER PERCUTANEOUS CORONARY ANGIOPLASTY (PART I)

Вісник проблем біології і медицини, 2018
It is well known that restenosis/thrombosis in stent placement site is one of the commonest complications in patients with ischemic heart disease (IHD) and percutaneous coronary angioplasty (PCA), and activation of intravascular thrombogenesis can be one
Storozhuk N. V., Makohonenko Ye. M., Storozhuk B. G., Lugovskoi E. V., Storozhuk L. O.   +4 more
doaj   +1 more source

©}æÚæ¹‡Ç ·~ ÂßüÌèØ ÿæÔ˜æô´ ×ð´ ÜæÖ·æÚè ¥õáÏèØ ÂæÎÂÔ ·è ·ëçá [PDF]

, 2010
§Úæ çÌßæÚè, ·Ô®âè® çÌßæÚè   +1 more
openalex   +1 more source

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

Molecular Oncology, Volume 19, Issue 7, Page 1897-1917, July 2025.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, Simon P. Gampenrieder, Daniel Egle, Christian F. Singer, Gabriel Rinnerthaler, Michael Hubalek, Katja Schmitz, Zsuzsanna Bago‐Horvath, Andreas Petzer, Sonja Heibl, Ellen Heitzer, Marija Balic, Michael Gnant   +14 more
wiley   +1 more source

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

Molecular Oncology, Volume 19, Issue 7, Page 2092-2108, July 2025.
In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Elin Borgen, Cecilie Bendigtsen Schirmer, Bjørnar Gilje, Øystein Garred, Jon Lømo, Marius Stensland, Oddmund Nordgård, Ragnhild Sørum Falk, Randi R. Mathiesen, Hege G. Russnes, Jon Amund Kyte, Bjørn Naume   +13 more
wiley   +1 more source

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, Volume 19, Issue 7, Page 1998-2013, July 2025.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source

The value of revascularization and adherence to therapy in the development of cardiovascular complications in long-term monitoring of patients with myocardial infarction of the right ventricle on the background of the Q-myocardial infarction of the left ventricular posterior wall [PDF]

Кардіохірургія та інтервенційна кардіологія, 2016
The aim – to evaluate the role of deferred revascularization and adherence to drug therapy as factors affecting long-term prognosis of patients with myocardial infarction (MI) of the right ventricle (RV) on the background of the Q-myocardial infarction ...
V.Y. Tseluyko, T.A. Lozova, V.P. Zheleznyy, O.S. Sasyuk   +3 more
doaj  

Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors

Molecular Oncology, Volume 19, Issue 7, Page 1935-1967, July 2025.
Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.
Yoshinori Hayashi, Janelle‐Cheri Millen, Romela Irene Ramos, Jennifer A. Linehan, Timothy G. Wilson, Dave S. B. Hoon, Matias A. Bustos   +6 more
wiley   +1 more source

KRAS and GNAS mutations in cell‐free DNA and in circulating epithelial cells in patients with intraductal papillary mucinous neoplasms—an observational pilot study

Molecular Oncology, Volume 19, Issue 7, Page 2144-2153, July 2025.
This study demonstrates that KRAS and GNAS mutations are more prevalent in patients with resected intraductal papillary mucinous neoplasms (IPMN) compared to those under clinical surveillance. GNAS mutations significantly differ between the two patient cohorts, indicating that their absence may serve as a potential biomarker to support conservative ...
Christine Nitschke, Marie Tölle, Philipp Walter, Kira Meißner, Mara Goetz, Jolanthe Kropidlowski, Andreas W. Berger, Jakob R. Izbicki, Felix Nickel, Thilo Hackert, Klaus Pantel, Harriet Wikman, Faik G. Uzunoglu   +12 more
wiley   +1 more source